Augmented type 2 inflammatory response in allergic rhinitis patients experiencing systemic reactions to house dust mite subcutaneous immunotherapy
Pediatric Allergy and Immunology · 2024
DOI: 10.1111/pai.14207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2024. Verfasst von Ping Ji und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Rhinitis, Allergic, Pyroglyphidae. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Subcutaneous immunotherapy (SCIT) can induce systemic reactions (SRs) in certain patients, but the underlying mechanisms remain to be fully elucidated.
Methods
AR patients who were undergoing standardized HDM SCIT (Alutard, ALK) between 2018 and 2022 were screened. Those who experienced two consecutive SRs were included in the study group. A control group was established, matched 1:1 by gender, age, and disease duration with the study group, who did not experience SRs during SCIT. Clinical and immunological parameters were recorded and analyzed both before SCIT and after 1 year of treatment.
Results
A total of 161 patients were included, with 79 (49.07%) in the study group. The study group had a higher proportion of AR combined asthma (26.8% vs. 51.8%, p < 0.001) and higher levels of sIgE to HDM and HDM components (all p < .001). Serum IL‐4 and IL‐13 levels in the study group were higher than those in the control group ( p < .05). The study group received a lower maintenance dosage of HDM extracts injections than control group due to SRs (50000SQ vs. 100000SQ, p < .05). After 1 year of SCIT, the VAS score, the lung function parameters of asthmatic patients over 14 years old significantly improved in both groups (all p < .05). After a 7‐day exposure to 20 μg/mL HDM extracts, the percentages of Th1, Th17, Tfh10, and Th17.1 in PBMCs decreased, while the Tfh13 cells significantly increased in the study group ( p < .05).
Conclusion
The type 2 inflammatory response is augmented in HDM‐induced AR patients who experienced SRs during SCIT. Despite this, SCIT remains effective in these patients when administered with low‐dosage allergen extracts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Yaqi Yang, Hao Chen, Rongfei Zhu
Zitieren
APA
Ji, P., Yang, L., Zhu, L., Hu, L., Wang, Y., Shi, C., Jiang, Q., Huang, N., Yang, Y., Chen, H., & Zhu, R. (2024). Augmented type 2 inflammatory response in allergic rhinitis patients experiencing systemic reactions to house dust mite subcutaneous immunotherapy. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.14207
Vancouver
Ji P, Yang L, Zhu L, Hu L, Wang Y, Shi C, et al. Augmented type 2 inflammatory response in allergic rhinitis patients experiencing systemic reactions to house dust mite subcutaneous immunotherapy. Pediatric Allergy and Immunology. 2024. doi:10.1111/pai.14207
BibTeX
@article{Ji2024,
author = {Ji, Ping and Yang, Lin and Zhu, Li and Hu, Lintao and Wang, Yin and Shi, Cancan and Jiang, Qing and Huang, Nan and Yang, Yaqi and Chen, Hao and Zhu, Rongfei},
title = {Augmented type 2 inflammatory response in allergic rhinitis patients experiencing systemic reactions to house dust mite subcutaneous immunotherapy},
journal = {Pediatric Allergy and Immunology},
year = {2024},
doi = {10.1111/pai.14207}
}
EUVIMED